These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35466013)

  • 1. SCOPE 2 - Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography.
    Bridges S; Thomas B; Radhakrishna G; Hawkins M; Holborow A; Hurt C; Mukherjee S; Nixon L; Crosby T; Gwynne S
    Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):e269-e280. PubMed ID: 35466013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oesophageal Chemoradiotherapy in the UK--current practice and future directions.
    Gwynne S; Falk S; Gollins S; Wills L; Bateman A; Cummins S; Grabsch H; Hawkins MA; Maggs R; Mukherjee S; Radhakrishna G; Roy R; Sharma RA; Spezi E; Crosby T
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):368-77. PubMed ID: 23489868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
    Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
    BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial.
    Pöttgen C; Gkika E; Stahl M; Abu Jawad J; Gauler T; Kasper S; Trarbach T; Herrmann K; Lehmann N; Jöckel KH; Lax H; Stuschke M
    Radiat Oncol; 2021 Mar; 16(1):59. PubMed ID: 33757534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoradiation versus oesophagectomy for locally advanced oesophageal cancer in Chinese patients: study protocol for a randomised controlled trial.
    Jia R; Yin W; Li S; Li R; Yang J; Shan T; Zhou D; Wang W; Wan L; Zhou F; Gao S
    Trials; 2019 Apr; 20(1):206. PubMed ID: 30971301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation based on
    Zhu H; Liu Q; Xu H; Mo M; Wang Z; Lu K; Zhou J; Chen J; Zheng X; Ye J; Ge X; Luo H; Liu Q; Deng J; Ai D; Hao S; Zhang J; Tseng IH; Song S; Chen Y; Zhao K
    Radiat Oncol; 2022 Jul; 17(1):134. PubMed ID: 35906623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
    Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
    BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of positron emission tomography scans for the evaluation of radiotherapy.
    Decazes P; Thureau S; Modzelewski R; Damilleville-Martin M; Bohn P; Vera P
    Cancer Radiother; 2020 Aug; 24(5):388-397. PubMed ID: 32448741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of Failure Following Dose-escalated Chemoradiotherapy for Fluorodeoxyglucose Positron Emission Tomography Staged Squamous Cell Carcinoma of the Oesophagus.
    Effeney R; Shaw T; Burmeister BH; Burmeister E; Harvey J; Mai GT; Thomas J; Barbour AP; Smithers BM; Pryor DI
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):642-649. PubMed ID: 30017206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definitive chemoradiotherapy for oesophageal cancer -- a promising start on an exciting journey.
    Rackley T; Leong T; Foo M; Crosby T
    Clin Oncol (R Coll Radiol); 2014 Sep; 26(9):533-40. PubMed ID: 24984577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma.
    Xia Y; Li YH; Chen Y; Liu Q; Zhang JH; Deng JY; Ai TS; Zhu HT; Badakhshi H; Zhao KL
    Int J Clin Oncol; 2018 Jun; 23(3):458-465. PubMed ID: 29435872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus.
    Hurt CN; Nixon LS; Griffiths GO; Al-Mokhtar R; Gollins S; Staffurth JN; Phillips CJ; Blazeby JM; Crosby TD
    BMC Cancer; 2011 Oct; 11():466. PubMed ID: 22035459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial.
    Mukherjee S; Hurt CN; Adams R; Bateman A; Bradley KM; Bridges S; Falk S; Griffiths G; Gwynne S; Jones CM; Markham PJ; Maughan T; Nixon LS; Radhakrishna G; Roy R; Schoenbuchner S; Sheikh H; Spezi E; Hawkins M; Crosby TDL
    EClinicalMedicine; 2023 Jul; 61():102059. PubMed ID: 37409323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-surgical versus surgical treatment for oesophageal cancer.
    Best LM; Mughal M; Gurusamy KS
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD011498. PubMed ID: 27021481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.
    Noordman BJ; Wijnhoven BPL; Lagarde SM; Boonstra JJ; Coene PPLO; Dekker JWT; Doukas M; van der Gaast A; Heisterkamp J; Kouwenhoven EA; Nieuwenhuijzen GAP; Pierie JEN; Rosman C; van Sandick JW; van der Sangen MJC; Sosef MN; Spaander MCW; Valkema R; van der Zaag ES; Steyerberg EW; van Lanschot JJB;
    BMC Cancer; 2018 Feb; 18(1):142. PubMed ID: 29409469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radiotherapy volume delineation based on (
    Encaoua J; Abgral R; Leleu C; El Kabbaj O; Caradec P; Bourhis D; Pradier O; Schick U
    Cancer Radiother; 2017 Jun; 21(4):267-275. PubMed ID: 28499658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stricture rate after chemoradiotherapy and radiotherapy for oesophageal squamous cell carcinoma: a 20-year experience.
    Hamer PW; Hight SC; Ward IG; Harris DL; Woodham BL; Flint RS
    ANZ J Surg; 2019 Apr; 89(4):367-371. PubMed ID: 30791194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT.
    Adamson D; Blazeby J; Porter C; Hurt C; Griffiths G; Nelson A; Sewell B; Jones M; Svobodova M; Fitzsimmons D; Nixon L; Fitzgibbon J; Thomas S; Millin A; Crosby T; Staffurth J; Byrne A
    Health Technol Assess; 2021 May; 25(31):1-144. PubMed ID: 34042566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
    BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis.
    Metzger JC; Wollschläger D; Miederer M; Vaupel P; Moehler M; Schmidberger H; Mayer A
    Strahlenther Onkol; 2017 Oct; 193(10):791-799. PubMed ID: 28770295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.